via Clinical Trials Arena by William Newton. Vosoritide’s uncertain long-term efficacy may limit European coverage of what could…
BioMarin
Source – Fierce Pharma. While BioMarin bested expectations with its second-quarter performance, the biotech is zeroed in on its two…
European Commission Decision expected Q3 2021Temporary Authorization for Use (ATU) Granted in France to Allow Access and Reimbursement…
via Healio/Endocrine Today Children with a common form of skeletal dysplasia saw persistent and sustained improvements in annualized…
SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment…
John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births.…
Established in 2018, The Chandler Project provides advocacy, awareness, research and support to those affected by achondroplasia, the most common form of dwarfism, and other skeletal dysplasias. TCP hosts the only event in North Amercia that brings together members of the skeletal dysplasia community physicians, researchers, biotech industries and more together at the annual Achondroplasia + Skeletal Dysplasia Research Conference.